Literature DB >> 24840971

Multiple sclerosis: Natalizumab to fingolimod--the washout whitewash.

Martin Stangel1, Olaf Stüve2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24840971     DOI： 10.1038/nrneurol.2014.82

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  The immune modulator FTY720 targets sphingosine 1-phosphate receptors.

Authors:  Volker Brinkmann; Michael D Davis; Christopher E Heise; Rainer Albert; Sylvain Cottens; Robert Hof; Christian Bruns; Eva Prieschl; Thomas Baumruker; Peter Hiestand; Carolyn A Foster; Markus Zollinger; Kevin R Lynch
Journal:  J Biol Chem       Date:  2002-04-19       Impact factor: 5.157

2.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

3.  Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Authors:  Mikael Cohen; Elisabeth Maillart; Ayman Tourbah; Jérôme De Sèze; Sandra Vukusic; David Brassat; Olivier Anne; Sandrine Wiertlewski; William Camu; Sylvie Courtois; Aurélie Ruet; Marc Debouverie; Emmanuelle Le Page; Olivier Casez; Olivier Heinzlef; Bruno Stankoff; Bertrand Bourre; Giovanni Castelnovo; Audrey Rico; Eric Berger; Jean-Philippe Camdessanche; Gilles Defer; Pierre Clavelou; Abdullatif Al Khedr; Hélène Zephir; Agnès Fromont; Caroline Papeix; Bruno Brochet; Jean Pelletier; Christine Lebrun
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

4.  Fingolimod after natalizumab and the risk of short-term relapse.

Authors:  Vilija G Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; Daniele L A Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

5.  Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

Authors:  P W O'Connor; A Goodman; L Kappos; F D Lublin; D H Miller; C Polman; R A Rudick; W Aschenbach; N Lucas
Journal:  Neurology       Date:  2011-05-04       Impact factor: 9.910

6.  Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

Authors:  M Krumbholz; I Meinl; T Kümpfel; R Hohlfeld; E Meinl
Journal:  Neurology       Date:  2008-10-21       Impact factor: 9.910

7.  Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

Authors:  P Kivisäkk; B C Healy; V Viglietta; F J Quintana; M A Hootstein; H L Weiner; S J Khoury
Journal:  Neurology       Date:  2009-06-02       Impact factor: 9.910

8.  Progressive multifocal leukoencephalopathy after natalizumab discontinuation.

Authors:  Andrew J Fine; Alfred Sorbello; Cindy Kortepeter; Linda Scarazzini
Journal:  Ann Neurol       Date:  2014-01       Impact factor: 10.422

9.  Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.

Authors:  O Stüve; P D Cravens; E M Frohman; J T Phillips; G M Remington; G von Geldern; S Cepok; M P Singh; J W Cohen Tervaert; M De Baets; D MacManus; D H Miller; E W Radü; E M Cameron; N L Monson; S Zhang; R Kim; B Hemmer; M K Racke
Journal:  Neurology       Date:  2008-11-05       Impact factor: 9.910
  9 in total
  1 in total

Review 1.  [Current aspects of therapy conversion for multiple sclerosis].

Authors:  P Kolber; F Luessi; S G Meuth; L Klotz; T Korn; C Trebst; B Tackenberg; B Kieseier; T Kümpfel; V Fleischer; H Tumani; B Wildemann; M Lang; P Flachenecker; U Meier; W Brück; V Limmroth; A Haghikia; H-P Hartung; M Stangel; R Hohlfeld; B Hemmer; R Gold; H Wiendl; F Zipp
Journal:  Nervenarzt       Date:  2015-10       Impact factor: 1.214
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.